Renhe Yikang：Topamax Topiramate was approved for marketing and deemed to have passed the consistency evaluation.
On May 29, according to the announcement on the NMPA official website, the Topiramate Oral Solution (Category 3 generic drug) submitted by Renhe Yikang Group was officially approved for marketing and was deemed to have passed the consistency evaluation.
Topiramate was originally developed by Johnson & Johnson Innovative Pharmaceuticals. It is a small-molecule antiepileptic drug with a diverse mechanism of action, including carbonic anhydrase inhibition, sodium channel blockade, and antagonism of GABA-A receptors, AMPA receptors, and kainate receptors. The drug was first approved in the UK in 1995 and entered the Chinese market in 2001, where the approved indication is epilepsy. In 2025, total sales of topiramate (tablets + capsules) in the terminal hospital market exceeded RMB 200 million, with topiramate tablets holding a dominant position, accounting for over 91% of the market share.
Looking at the overall market, the annual sales of antiepileptic drugs in domestic terminal hospitals have exceeded RMB 5.9 billion, with the industry scale growing steadily. Topiramate tablets,凭借其 clinical value, consistently rank within the top 10 antiepileptic drugs by sales revenue and are a core variety commonly used in clinical practice. Its diverse pharmacological mechanisms also provide a reliable treatment option for epilepsy patients.
Buy Topiramate（Topamax） online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
